maddstone

Für viele ist @x nur ein Boxring. Punchlines werden rausgehauen, im Austausch scheint es nur darum zu gehen den anderen auffliegen zu lassen oder gar zu "zerstören", den Punkt final zu machen. Wie wärs mal mit respektvollen Umgang und fairen Debatten auch mit Andersdenkenden?🤔

@JessieChimni @ny1972_47 Don’t you find the sp movement strange too?

@ny1972_47 @maddstone1 *pace

I put some lotto money into $1.5 $FATE Nov 2026 Options. Bought for $.9.

@mdurgin1 Why just ln pivotal?

@maddstone1 Yeah, the 819 kidney data looks really amazing. It appears to be rapid and durable. I am expecting a 80-90% CRR rate @ 6 months, which would be revolutionary for this disease.

Is the phase 2 Endponint 6 month CRR the problem for $fate? We don’t know if they can reach that

@jreichelt Deutsche Spencer Pratt

@mdurgin1 Ah, didnt find it, 40% patients crr at 6 month would be approvable they say

@maddstone1 Well, as of their last data release they have 100% CRR rate for LN patients at 6 months. Small N=2. But, also 2/3 CRR rate @ 2 months.

Plus quiet higher phase 2 dosage? $fate

@dillonsquire_ Why no drop on Spotify yet?

@maddstone1 Thank you ♥️

the riff for dirtbike #songwriter #guitarist #guitar

@ny1972_47 @JessieChimni The pivotal is limited to LN, might this be the markets problem?

@maddstone1 @JessieChimni This is a curse on the SP: Company aims to complete the enrollment of the RECLAIM – LN clinical study approximately 15 months from commencement. 15 months for each site to come up with 3 pts?

@ny1972_47 @JessieChimni Endpoint is 6 month, so 9 month for 53 patients?

JOE ROGAN WENT FULL PALESTINE RETARD, BUT GADDY KEPT IT COOL!!!😎😘😘😘

@SloHoopsFan Such a pussy

Wow, Pelinka actually mogged LeBron by giving the ball to Reddick 😳 What a Chad!

@tuduylinh @Hooks_JP Is 836 the therapy of Choice in combination therapy’s of the future

@Hooks_JP the pace of enrolment for FT836 is always a good sign bc it is driven by word of mouth. patients w cancer r desperate; AEs may not be taht important to them but efficacy sure is. that Bob will provide update of 836 at ASCO in June with a larger cohort is another clue. $fate

$FATE FT836 As of April 20, 2026, nine patients have been treated with FT836 in the Phase 1 basket solid tumor study, including patients in the cetuximab combination (Regimen C) and trastuzumab combination (Regimen E) arms. To date, FT836 has been well-tolerated with no ICANS, GvHD, CRS, or dose-limiting toxicities at dose level 1 of Regimen C, supporting its potential as a broadly accessible treatment with a favorable emerging safety profile. The Company expects to present updated FT836 clinical data across a larger patient cohort at the American Society of Clinical Oncology Annual Meeting in June 2026. Additionally, the FDA has cleared an IND for an investigator-initiated trial for FT836 in combination with daratumumab for a novel treatment strategy in multiple myeloma to be conducted at the Medical College of Wisconsin. Patient treatment in this IIT is expected to commence in mid-2026. The Company plans to provide further updates on FT836 at American Society of Gene and Cell TherapyAnnual Meeting and at American Society of Clinical Oncology in May of 2026.

@ny1972_47 @JessieChimni So let’s see, thank you bon

@maddstone1 @JessieChimni CDRP is just the preconditioning, the hatred on FATE is like a stage 4 MSS CRC that will require FT836.

@ny1972_47 @JessieChimni Right now we defending 200 mio

@ny1972_47 @JessieChimni How much of a market cap would you grand fate

@JessieChimni @ny1972_47 Hey Bon, is there a stinker in today’s PR?

@ny1972_47 I did not check. May do that as well. Thanks

@MofeekS @DrPaulyDeSantis @Restructuring__ @jonasjbc I just don’t get the so crash

@maddstone1 @DrPaulyDeSantis @Restructuring__ @jonasjbc Up 40% in the past month. Long list of catalysts incoming. Trading near cash. Tell me more.

Cathie Wood’s ability to collect management fees will be studied for decades. Truly one of the worst investors of all time, while making tens of millions in fees. Some of the worst trades include: - TDOC: made it ARKK’s largest position at ~$80/sh.; today: ~$7/sh. - Zoom: loaded up around ~$300/sh.; today: ~$110/sh. - Nvidia: sold almost all of it in January 2023 at ~$20/sh.; today: ~$220/sh. Amazing track record.

@MofeekS @DrPaulyDeSantis @Restructuring__ @jonasjbc Todays sp action adds to the thesis

@DrPaulyDeSantis @Restructuring__ @jonasjbc Calling $FATE a disaster is absurd.